Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study

Category Primary study
JournalJournal of Clinical Oncology
Year 2019
This article has no abstract
Epistemonikos ID: b2181148c573e6fe38848f5ed964413a18e1b417
First added on: Feb 11, 2025